Humacyte, Inc. (HUMA)
0.6939
+0.01
(+1.80%)
USD |
NASDAQ |
Aug 27, 16:00
0.692
0.00 (0.00%)
After-Hours: 17:15
Humacyte Debt to Equity Ratio : 2.117 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.117 |
| March 31, 2026 | 5.669 |
| December 31, 2025 | 20.86 |
| September 30, 2025 | -10.64 |
| June 30, 2025 | 20.65 |
| March 31, 2025 | 2.281 |
| December 31, 2024 | -1.528 |
| September 30, 2024 | -0.271 |
| June 30, 2024 | -0.6337 |
| March 31, 2024 | 0.71 |
| December 31, 2023 | 4.290 |
| September 30, 2023 | 0.5269 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.3284 |
| March 31, 2023 | 0.6169 |
| December 31, 2022 | 0.4336 |
| September 30, 2022 | 0.4288 |
| June 30, 2022 | 0.3583 |
| March 31, 2022 | 0.4917 |
| December 31, 2021 | 0.4189 |
| September 30, 2021 | 0.5564 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.0001 |
| December 31, 2020 | 0.4084 |
| September 30, 2020 | 0.0009 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Amgen, Inc. | 4.903 |
| Altimmune, Inc. | 0.076 |
| Protalix Biotherapeutics, Inc. | 0.1289 |
| Taysha Gene Therapies, Inc. | 0.1469 |
| Agenus, Inc. | -1.458 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 138.09M |
| Total Liabilities (Quarterly) | 106.83M |
| Shareholders Equity (Quarterly) | 31.26M |
| Current Ratio | 6.207 |
| Net Debt Paydown Yield | 1.48% |